Andere Sprachen Yabao Pharmaceutical Group Co., Ltd

Aktien

A0M4KQ

CNE000001CM5

600351

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 15.05.2024			% 5 Tage	% 1. Jan.
6,68 ^CNY	-1,62 %		-0,15 %	-3,19 %

25.04.	Yabao Pharmaceutical Group Co., Ltd. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
25.04.	Yabao Pharmaceutical Group Co., Ltd berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25.04.
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	25.04.
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules	16.04.
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	02.04.
Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback.	05.02.
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27.10.23
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	10.10.23
Yabao Pharmaceutical Group Co., Ltd(XSSC:600351) added to S&P Global BMI Index	18.09.23
Hunan Caprico Biotechnologies Co., Ltd. announced that it has received funding from Guangzhou Huangpu Biomedical Fund Management Co., Ltd., Yabao Pharmaceutical Group Co., Ltd	18.09.23
Yabao Pharmaceutical Takes Over Rights of Traditional Chinese Medicine for 26 Million Yuan	08.08.23
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	03.08.23
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	04.07.23
Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.	09.05.23
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25.04.23
Yabao Pharmaceutical Unit Submits FDA Application for Osteoarthritis Drug	13.04.23
Yabao Pharmaceutical Unit's Sorafenib Tablets Enters US Markets	16.11.22
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	27.10.22
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22.08.22
Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor	03.08.22
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	27.04.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Yabao Pharmaceutical Group Co., Ltd

Aktien

A0M4KQ

CNE000001CM5

600351

Andere Sprachen

Filter